<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0185-3325</journal-id>
<journal-title><![CDATA[Salud mental]]></journal-title>
<abbrev-journal-title><![CDATA[Salud Ment]]></abbrev-journal-title>
<issn>0185-3325</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0185-33252018000600279</article-id>
<article-id pub-id-type="doi">10.17711/sm.0185-3325.2018.040</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Evaluation of the response of lisdexamfetamine in children and adolescents with ADHD: quasi-experimental study]]></article-title>
<article-title xml:lang="es"><![CDATA[Evaluación de la respuesta de la lisdexanfetamina en niños y adolescentes con TDAH: estudio cuasiexperimental]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barragán Pérez]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Beristain]]></surname>
<given-names><![CDATA[Juan Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hidalgo Gutiérrez]]></surname>
<given-names><![CDATA[Ricardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Infantil de México Federico Gómez, Ciudad de México, México Departamento de Neurología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>41</volume>
<numero>6</numero>
<fpage>279</fpage>
<lpage>286</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0185-33252018000600279&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0185-33252018000600279&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0185-33252018000600279&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders. Although lisdexamfetamine dimesylate (LDX) offers a treatment alternative, clinical evidence of LDX for ADHD has not been explored in Latin American pediatric population.  Objective . To evaluate the LDX response in Mexican pediatric patients with ADHD.  Method . We designed a quasi-experimental, uncontrolled before and after study to evaluate the LDX response in patients with severe ADHD. We established a diagnosis of ADHD according to DSM-5 criteria. We formed three groups: without previous treatment (group A), in treatment with stimulant drugs (group B) or in treatment with non-stimulant drugs (group C). Prior to the start of the study, letters of consent and informed consent were signed. We evaluated the effect of LDX based on the difference between ADHD-RS scores at the beginning and after six months.  Results . We recruited a total of 144 patients (group A: 48 patients, group B: 57 patients, group C: 39 patients). All the groups showed a significant decrease in the mean score of ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) at six months (group A 37.57 vs. 22.34, p &lt;.01), (group B 36.72 vs. 24.45; p &lt;. 01), (group C 38.54 vs. 24.3, p &lt;.01). Fewer than 30% of the subjects showed a significant adverse reaction, the most frequent ones being: sleep disturbance (primary insomnia) 24% and decreased appetite in 20%.  Discussion and conclusion . Treatment with LDX is an effective, well-tolerated pharmacological option for Mexican pediatric patients with ADHD.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción . El trastorno por déficit de atención con hiperactividad (TDAH) es uno de los trastornos del neurodesarrollo más comunes. Aunque el dimesilato de lisdexanfetamina (LDX) ofrece una alternativa de tratamiento, la evidencia clínica de LDX para TDAH no se ha explorado en población pediátrica latinoamericana.  Objetivo . Evaluar la respuesta de LDX en pacientes pediátricos mexicanos con TDAH.  Método . Diseñamos un estudio cuasiexperimental no controlado de antes y después para evaluar la respuesta de LDX en pacientes con TDAH grave. Establecimos el diagnóstico de TDAH de acuerdo con criterios del DSM-5. Conformamos tres grupos: sin tratamiento previo (grupo A), en tratamiento con fármacos estimulantes (grupo B) o en tratamiento con fármacos no estimulantes (grupo C). Previo al inicio del estudio se firmaron las cartas de consentimiento y asentimiento informado. Evaluamos el efecto de LDX con base en la diferencia de los puntajes de ADHD-RS al inicio y posterior a seis meses.  Resultados . Reclutamos un total de 144 pacientes (grupo A: 48 pacientes, grupo B: 57 pacientes, grupo C: 39 pacientes). Todos los grupos mostraron una disminución significativa en la media de puntaje de ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) a los seis meses (grupo A 37.57 vs. 22.34; p &lt; .01), (grupo B 36.72 vs. 24.45; p &lt; .01), (grupo C 38.54 vs. 24.3; p &lt; .01). Menos del 30% de los sujetos presentó alguna reacción adversa importante, siendo las más frecuentes: alteraciones del sueño (insomnio primario) 24% y disminución del apetito en 20%.  Discusión y conclusión . El tratamiento con LDX es una opción farmacológica efectiva y bien tolerada para pacientes pediátricos mexicanos con TDAH.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[ADHD]]></kwd>
<kwd lng="en"><![CDATA[lisdexamfetamine dimesylate]]></kwd>
<kwd lng="en"><![CDATA[attention deficit]]></kwd>
<kwd lng="en"><![CDATA[motor hyperactivity]]></kwd>
<kwd lng="es"><![CDATA[TDAH]]></kwd>
<kwd lng="es"><![CDATA[dimesilato de lisdexanfetamina]]></kwd>
<kwd lng="es"><![CDATA[déficit de atención]]></kwd>
<kwd lng="es"><![CDATA[hiperactividad motora]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<collab>American Academy of Pediatrics</collab>
<article-title xml:lang=""><![CDATA[ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>2011</year>
<volume>128</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1007-22</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[E.]]></surname>
<given-names><![CDATA[Barragán]]></given-names>
</name>
<name>
<surname><![CDATA[D.]]></surname>
<given-names><![CDATA[Breuer]]></given-names>
</name>
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Döpfner]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children with ADHD]]></article-title>
<source><![CDATA[Journal of Attention Disorders]]></source>
<year>2017</year>
<volume>21</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>433-41</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[E.]]></surname>
<given-names><![CDATA[Barragán-Pérez]]></given-names>
</name>
<name>
<surname><![CDATA[F.]]></surname>
<given-names><![CDATA[de la Peña-Olvera]]></given-names>
</name>
<name>
<surname><![CDATA[S.]]></surname>
<given-names><![CDATA[Ortiz-León]]></given-names>
</name>
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Ruiz-García]]></given-names>
</name>
<name>
<surname><![CDATA[J.]]></surname>
<given-names><![CDATA[Hernández-Aguilar]]></given-names>
</name>
<name>
<surname><![CDATA[L.]]></surname>
<given-names><![CDATA[Palacios-Cruz]]></given-names>
</name>
<name>
<surname><![CDATA[A.]]></surname>
<given-names><![CDATA[Suárez-Reynaga]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primer consenso latinoamericano de trastorno por déficit de atención e hiperactividad]]></article-title>
<source><![CDATA[Boletín médico del hospital infantil de México]]></source>
<year>2007</year>
<volume>64</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>326-43</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[J.]]></surname>
<given-names><![CDATA[Biederman]]></given-names>
</name>
<name>
<surname><![CDATA[S.]]></surname>
<given-names><![CDATA[Krishnan]]></given-names>
</name>
<name>
<surname><![CDATA[Y.]]></surname>
<given-names><![CDATA[Zhang]]></given-names>
</name>
<name>
<surname><![CDATA[J. J.]]></surname>
<given-names><![CDATA[McGough]]></given-names>
</name>
<name>
<surname><![CDATA[R. L.]]></surname>
<given-names><![CDATA[Findling]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study]]></article-title>
<source><![CDATA[Clinical Therapeutics]]></source>
<year>2007</year>
<volume>29</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>450-63</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[S. W.]]></surname>
<given-names><![CDATA[Boellner]]></given-names>
</name>
<name>
<surname><![CDATA[J. G.]]></surname>
<given-names><![CDATA[Stark]]></given-names>
</name>
<name>
<surname><![CDATA[S.]]></surname>
<given-names><![CDATA[Krishnan]]></given-names>
</name>
<name>
<surname><![CDATA[Y.]]></surname>
<given-names><![CDATA[Zhang]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover]]></article-title>
<source><![CDATA[Clinical Therapeutics]]></source>
<year>2010</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>252-64</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[B.]]></surname>
<given-names><![CDATA[Bolea-Alamañac]]></given-names>
</name>
<name>
<surname><![CDATA[D. J.]]></surname>
<given-names><![CDATA[Nutt]]></given-names>
</name>
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Adamou]]></given-names>
</name>
<name>
<surname><![CDATA[P.]]></surname>
<given-names><![CDATA[Asherson]]></given-names>
</name>
<name>
<surname><![CDATA[S.]]></surname>
<given-names><![CDATA[Bazire]]></given-names>
</name>
<name>
<surname><![CDATA[D.]]></surname>
<given-names><![CDATA[Coghill]]></given-names>
</name>
<name>
<surname><![CDATA[S. J.]]></surname>
<given-names><![CDATA[Young]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology]]></article-title>
<source><![CDATA[Journal of Psychopharmacology]]></source>
<year>2014</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>179-203</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<collab>CADDRA.</collab>
<source><![CDATA[Canadian ADHD practice guidelines]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Toronto ]]></publisher-loc>
<publisher-name><![CDATA[Canadian Attention Deficit Hyperactivity Disorder Resource Alliance]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="">
<collab>COFEPRIS.</collab>
<source><![CDATA[2015]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D. R.]]></surname>
<given-names><![CDATA[Coghill]]></given-names>
</name>
<name>
<surname><![CDATA[B.]]></surname>
<given-names><![CDATA[Caballero]]></given-names>
</name>
<name>
<surname><![CDATA[S.]]></surname>
<given-names><![CDATA[Sorooshian]]></given-names>
</name>
<name>
<surname><![CDATA[R.]]></surname>
<given-names><![CDATA[Civil]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Systematic Review of the Safety of Lisdexamfetamine Dimesylate]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2014</year>
<volume>28</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>497-511</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D.]]></surname>
<given-names><![CDATA[Coghill]]></given-names>
</name>
<name>
<surname><![CDATA[T.]]></surname>
<given-names><![CDATA[Banaschewski]]></given-names>
</name>
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Lecendreux]]></given-names>
</name>
<name>
<surname><![CDATA[C.]]></surname>
<given-names><![CDATA[Soutullo]]></given-names>
</name>
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Johnson]]></given-names>
</name>
<name>
<surname><![CDATA[A.]]></surname>
<given-names><![CDATA[Zuddas]]></given-names>
</name>
<name>
<surname><![CDATA[L.]]></surname>
<given-names><![CDATA[Squires]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder]]></article-title>
<source><![CDATA[European Neuropsychopharmacology]]></source>
<year>2013</year>
<volume>23</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1208-18</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[F.]]></surname>
<given-names><![CDATA[de la Peña]]></given-names>
</name>
<name>
<surname><![CDATA[E.]]></surname>
<given-names><![CDATA[Barragán Pérez]]></given-names>
</name>
<name>
<surname><![CDATA[L. A.]]></surname>
<given-names><![CDATA[Rohde]]></given-names>
</name>
<name>
<surname><![CDATA[L. R. P.]]></surname>
<given-names><![CDATA[Durán]]></given-names>
</name>
<name>
<surname><![CDATA[P. Z.]]></surname>
<given-names><![CDATA[Ramírez]]></given-names>
</name>
<name>
<surname><![CDATA[R. E. U.]]></surname>
<given-names><![CDATA[Flores]]></given-names>
</name>
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Larraguibel]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Algoritmo de tratamiento multimodal para escolares latinoamericanos con trastorno por déficit de atención con hiperactividad - TDAH]]></article-title>
<source><![CDATA[Salud Mental]]></source>
<year>2009</year>
<volume>32</volume>
<numero>S1</numero>
<issue>S1</issue>
<page-range>17-29</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[U.]]></surname>
<given-names><![CDATA[Diaz-Orueta]]></given-names>
</name>
<name>
<surname><![CDATA[M. A.]]></surname>
<given-names><![CDATA[Fernandez-Fernandez]]></given-names>
</name>
<name>
<surname><![CDATA[M. D.]]></surname>
<given-names><![CDATA[Morillo-Rojas]]></given-names>
</name>
<name>
<surname><![CDATA[G.]]></surname>
<given-names><![CDATA[Climent]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of lisdexamphetamine to improve the behavioural and cognitive symptoms of attention deficit hyperactivity disorder: treatment monitored by means of the AULA Nesplora virtual reality test]]></article-title>
<source><![CDATA[Revista de neurologia]]></source>
<year>2016</year>
<volume>63</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-27</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[J. C.]]></surname>
<given-names><![CDATA[Ermer]]></given-names>
</name>
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Pennick]]></given-names>
</name>
<name>
<surname><![CDATA[G.]]></surname>
<given-names><![CDATA[Frick]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy]]></article-title>
<source><![CDATA[Clinical Drug Investigation]]></source>
<year>2016</year>
<volume>36</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>341-56</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[S. V.]]></surname>
<given-names><![CDATA[Faraone]]></given-names>
</name>
<name>
<surname><![CDATA[J.]]></surname>
<given-names><![CDATA[Sergeant]]></given-names>
</name>
<name>
<surname><![CDATA[C.]]></surname>
<given-names><![CDATA[Gillberg]]></given-names>
</name>
<name>
<surname><![CDATA[J.]]></surname>
<given-names><![CDATA[Biederman]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The worldwide prevalence of ADHD: is it an American condition?]]></article-title>
<source><![CDATA[World psychiatry]]></source>
<year>2003</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>104-13</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[S. V.]]></surname>
<given-names><![CDATA[Faraone]]></given-names>
</name>
<name>
<surname><![CDATA[J.]]></surname>
<given-names><![CDATA[Buitelaar]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis]]></article-title>
<source><![CDATA[European Child &amp; Adolescent Psychiatry]]></source>
<year>2010</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>353-64</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[R. L.]]></surname>
<given-names><![CDATA[Findling]]></given-names>
</name>
<name>
<surname><![CDATA[A. C.]]></surname>
<given-names><![CDATA[Childress]]></given-names>
</name>
<name>
<surname><![CDATA[A. J.]]></surname>
<given-names><![CDATA[Cutler]]></given-names>
</name>
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Gasior]]></given-names>
</name>
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Hamdani]]></given-names>
</name>
<name>
<surname><![CDATA[M. C.]]></surname>
<given-names><![CDATA[Ferreira-Cornwell]]></given-names>
</name>
<name>
<surname><![CDATA[L.]]></surname>
<given-names><![CDATA[Squires]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and Safety of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder]]></article-title>
<source><![CDATA[Journal of the American Academy of Child &amp; Adolescent Psychiatry]]></source>
<year>2011</year>
<volume>50</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>395-405</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[R. L.]]></surname>
<given-names><![CDATA[Findling]]></given-names>
</name>
<name>
<surname><![CDATA[A. J.]]></surname>
<given-names><![CDATA[Cutler]]></given-names>
</name>
<name>
<surname><![CDATA[K.]]></surname>
<given-names><![CDATA[Saylor]]></given-names>
</name>
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Gasior]]></given-names>
</name>
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Hamdani]]></given-names>
</name>
<name>
<surname><![CDATA[M. C.]]></surname>
<given-names><![CDATA[Ferreira-Cornwell]]></given-names>
</name>
<name>
<surname><![CDATA[A. C.]]></surname>
<given-names><![CDATA[Childress]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Long-Term Open-Label Safety and Effectiveness Trial of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder]]></article-title>
<source><![CDATA[Journal of Child and Adolescent Psychopharmacology]]></source>
<year>2013</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-21</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[V.]]></surname>
<given-names><![CDATA[Gonzalez-Covarrubias]]></given-names>
</name>
<name>
<surname><![CDATA[J. J.]]></surname>
<given-names><![CDATA[Martínez-Magaña]]></given-names>
</name>
<name>
<surname><![CDATA[R.]]></surname>
<given-names><![CDATA[Coronado-Sosa]]></given-names>
</name>
<name>
<surname><![CDATA[B.]]></surname>
<given-names><![CDATA[Villegas-Torres]]></given-names>
</name>
<name>
<surname><![CDATA[A. D.]]></surname>
<given-names><![CDATA[Genis-Mendoza]]></given-names>
</name>
<name>
<surname><![CDATA[P.]]></surname>
<given-names><![CDATA[Canales-Herrerias]]></given-names>
</name>
<name>
<surname><![CDATA[X.]]></surname>
<given-names><![CDATA[Soberón]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations]]></article-title>
<source><![CDATA[Pharmaceutical Research]]></source>
<year>2016</year>
<volume>33</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2644-52</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D.]]></surname>
<given-names><![CDATA[Goodman]]></given-names>
</name>
<name>
<surname><![CDATA[S. V.]]></surname>
<given-names><![CDATA[Faraone]]></given-names>
</name>
<name>
<surname><![CDATA[L. A.]]></surname>
<given-names><![CDATA[Adler]]></given-names>
</name>
<name>
<surname><![CDATA[B.]]></surname>
<given-names><![CDATA[Dirks]]></given-names>
</name>
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Hamdani]]></given-names>
</name>
<name>
<surname><![CDATA[R.]]></surname>
<given-names><![CDATA[Weisler]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interpreting ADHD rating scale scores: linking ADHD rating scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD]]></article-title>
<source><![CDATA[Primary Psychiatry]]></source>
<year>2010</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>44</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[P.]]></surname>
<given-names><![CDATA[Hodgkins]]></given-names>
</name>
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Shaw]]></given-names>
</name>
<name>
<surname><![CDATA[H.]]></surname>
<given-names><![CDATA[Caci]]></given-names>
</name>
<name>
<surname><![CDATA[S.]]></surname>
<given-names><![CDATA[Young]]></given-names>
</name>
<name>
<surname><![CDATA[J.]]></surname>
<given-names><![CDATA[Kahle]]></given-names>
</name>
<name>
<surname><![CDATA[A. G.]]></surname>
<given-names><![CDATA[Woods]]></given-names>
</name>
<name>
<surname><![CDATA[L. E.]]></surname>
<given-names><![CDATA[Arnold]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: Effects of treatment and non-treatment]]></article-title>
<source><![CDATA[BMC Medicine]]></source>
<year>2012</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>99</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Y.]]></surname>
<given-names><![CDATA[Li]]></given-names>
</name>
<name>
<surname><![CDATA[J.]]></surname>
<given-names><![CDATA[Gao]]></given-names>
</name>
<name>
<surname><![CDATA[S.]]></surname>
<given-names><![CDATA[He]]></given-names>
</name>
<name>
<surname><![CDATA[Y.]]></surname>
<given-names><![CDATA[Zhang]]></given-names>
</name>
<name>
<surname><![CDATA[Q.]]></surname>
<given-names><![CDATA[Wang]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments]]></article-title>
<source><![CDATA[Molecular Neurobiology]]></source>
<year>2017</year>
<volume>54</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>6655-69</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[C. A.]]></surname>
<given-names><![CDATA[Lopez]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual diagnóstico y estadístico de los trastornos mentales: DSM-5]]></source>
<year>2014</year>
<publisher-name><![CDATA[Editorial Médica Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="book">
<collab>National Institute for Health and Care Excellence</collab>
<source><![CDATA[Attention deficit hyperactivity disorder: diagnosis and management]]></source>
<year>2018</year>
<publisher-name><![CDATA[Guidance and guidelines NICE]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[E. B.]]></surname>
<given-names><![CDATA[Pérez]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Las enfermedades neuropsiquiátricas en Latinoamérica y sus retos]]></article-title>
<source><![CDATA[Consejo Editorial 2009-2010]]></source>
<year>2010</year>
<volume>78</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>173</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[G. V.]]></surname>
<given-names><![CDATA[Polanczyk]]></given-names>
</name>
<name>
<surname><![CDATA[E. G.]]></surname>
<given-names><![CDATA[Willcutt]]></given-names>
</name>
<name>
<surname><![CDATA[G. A.]]></surname>
<given-names><![CDATA[Salum]]></given-names>
</name>
<name>
<surname><![CDATA[C.]]></surname>
<given-names><![CDATA[Kieling]]></given-names>
</name>
<name>
<surname><![CDATA[L. A.]]></surname>
<given-names><![CDATA[Rohde]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis]]></article-title>
<source><![CDATA[International Journal of Epidemiology]]></source>
<year>2014</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>434-42</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[G.]]></surname>
<given-names><![CDATA[Polanczyk]]></given-names>
</name>
<name>
<surname><![CDATA[M. S.]]></surname>
<given-names><![CDATA[de Lima]]></given-names>
</name>
<name>
<surname><![CDATA[B. L.]]></surname>
<given-names><![CDATA[Horta]]></given-names>
</name>
<name>
<surname><![CDATA[J.]]></surname>
<given-names><![CDATA[Biederman]]></given-names>
</name>
<name>
<surname><![CDATA[L. A.]]></surname>
<given-names><![CDATA[Rohde]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis]]></article-title>
<source><![CDATA[American Journal of Psychiatry]]></source>
<year>2007</year>
<volume>164</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>942-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[S.]]></surname>
<given-names><![CDATA[Punja]]></given-names>
</name>
<name>
<surname><![CDATA[C. H.]]></surname>
<given-names><![CDATA[Schmid]]></given-names>
</name>
<name>
<surname><![CDATA[L.]]></surname>
<given-names><![CDATA[Hartling]]></given-names>
</name>
<name>
<surname><![CDATA[L.]]></surname>
<given-names><![CDATA[Urichuk]]></given-names>
</name>
<name>
<surname><![CDATA[C. J.]]></surname>
<given-names><![CDATA[Nikles]]></given-names>
</name>
<name>
<surname><![CDATA[S.]]></surname>
<given-names><![CDATA[Vohra]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[To meta-analyze or not to meta-analyze? A combined meta-analysis of N-of-1 trial data with RCT data on amphetamines and methylphenidate for pediatric ADHD]]></article-title>
<source><![CDATA[Journal of Clinical Epidemiology]]></source>
<year>2016</year>
<volume>76</volume>
<page-range>76-81</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[S.]]></surname>
<given-names><![CDATA[Punja]]></given-names>
</name>
<name>
<surname><![CDATA[L.]]></surname>
<given-names><![CDATA[Shamseer]]></given-names>
</name>
<name>
<surname><![CDATA[L.]]></surname>
<given-names><![CDATA[Hartling]]></given-names>
</name>
<name>
<surname><![CDATA[L.]]></surname>
<given-names><![CDATA[Urichuk]]></given-names>
</name>
<name>
<surname><![CDATA[B.]]></surname>
<given-names><![CDATA[Vandermeer]]></given-names>
</name>
<name>
<surname><![CDATA[J.]]></surname>
<given-names><![CDATA[Nikles]]></given-names>
</name>
<name>
<surname><![CDATA[S.]]></surname>
<given-names><![CDATA[Vohra]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Riera]]></given-names>
</name>
<name>
<surname><![CDATA[X.]]></surname>
<given-names><![CDATA[Castells]]></given-names>
</name>
<name>
<surname><![CDATA[A.]]></surname>
<given-names><![CDATA[Tobias]]></given-names>
</name>
<name>
<surname><![CDATA[R.]]></surname>
<given-names><![CDATA[Cunill]]></given-names>
</name>
<name>
<surname><![CDATA[L.]]></surname>
<given-names><![CDATA[Blanco]]></given-names>
</name>
<name>
<surname><![CDATA[D.]]></surname>
<given-names><![CDATA[Capellà]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>2017</year>
<volume>234</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>2657-71</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Sosa-Macías]]></given-names>
</name>
<name>
<surname><![CDATA[E.]]></surname>
<given-names><![CDATA[Teran]]></given-names>
</name>
<name>
<surname><![CDATA[W.]]></surname>
<given-names><![CDATA[Waters]]></given-names>
</name>
<name>
<surname><![CDATA[M. M.]]></surname>
<given-names><![CDATA[Fors]]></given-names>
</name>
<name>
<surname><![CDATA[C.]]></surname>
<given-names><![CDATA[Altamirano]]></given-names>
</name>
<name>
<surname><![CDATA[H.]]></surname>
<given-names><![CDATA[Jung-Cook]]></given-names>
</name>
<name>
<surname><![CDATA[F.]]></surname>
<given-names><![CDATA[Hernández]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America]]></article-title>
<source><![CDATA[Pharmacogenomics]]></source>
<year>2016</year>
<volume>17</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1741-7</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[Stuhec]]></given-names>
</name>
<name>
<surname><![CDATA[B.]]></surname>
<given-names><![CDATA[Munda]]></given-names>
</name>
<name>
<surname><![CDATA[V.]]></surname>
<given-names><![CDATA[Svab]]></given-names>
</name>
<name>
<surname><![CDATA[I.]]></surname>
<given-names><![CDATA[Locatelli]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: A meta-analysis with focus on bupropion]]></article-title>
<source><![CDATA[Journal of Affective Disorders]]></source>
<year>2015</year>
<volume>178</volume>
<page-range>149-59</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[L. J.]]></surname>
<given-names><![CDATA[Wang]]></given-names>
</name>
<name>
<surname><![CDATA[K. C.]]></surname>
<given-names><![CDATA[Yang]]></given-names>
</name>
<name>
<surname><![CDATA[S. Y.]]></surname>
<given-names><![CDATA[Lee]]></given-names>
</name>
<name>
<surname><![CDATA[C. J.]]></surname>
<given-names><![CDATA[Yang]]></given-names>
</name>
<name>
<surname><![CDATA[T. S.]]></surname>
<given-names><![CDATA[Huang]]></given-names>
</name>
<name>
<surname><![CDATA[T. L.]]></surname>
<given-names><![CDATA[Lee]]></given-names>
</name>
<name>
<surname><![CDATA[Y. C.]]></surname>
<given-names><![CDATA[Shyu]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan]]></article-title>
<source><![CDATA[PLoS ONE]]></source>
<year>2016</year>
<volume>11</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>0161061</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
